Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338394 | 0.91 | MAPK14 (0.47) | MAPK14RXRA | |
| SCHEMBL3110329 | 0.88 | MAPK14 (0.49) | MAPK14RXRA | |
| SCHEMBL3106203 | 0.88 | MAPK14 (0.61) | MAPK14HPGD | |
| SCHEMBL3121346 | 0.88 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL1140024 | 0.88 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL3115360 | 0.87 | MAPK14 (0.49) | MAPK14HPGD | |
| SCHEMBL1140442 | 0.85 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL3339036 | 0.85 | HPGD (0.53) | MAPK14HPGDTSHRNPSR1 | |
| SCHEMBL3341669 | 0.84 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL1399865 | 0.83 | KDM4E (0.45) | MAPK14MTHFD2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-7696215-B2 | 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| EP-1856062-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090143-A1 | 4-0X0QUINAZ0LIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152169-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL2RA | MAPK14 1418/4885FGFR1 382/4885SRC 1921/4885 |
| US-20090124604-A1 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES | IL2, IL1A, IL1B | MAPK14 1400/4885FGFR1 380/4885SRC 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.